Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab

• DOI: 10.1007/s10792-024-03107-8
• Publication Date: 2024-04-16T06:01:56Z
• Authors: Hiroki Takizawa; Masayuki Yasuda; Keisuke Hoshi; Tatsu Okabe; Hiroshi Kunikata; Toru Nakazawa
• Keywords: Male; Aged, 80 and over; Optic Disk; Middle Aged; Antibodies, Monoclonal, Humanized; Macular Degeneration; Ranibizumab; Intravitreal Injections; Humans; Female; Longitudinal Studies; Biosimilar Pharmaceuticals; Aged; Retrospective Studies

To assess ocular blood flow (OBF) changes in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal injections of ranibizumab biosimilar (IVRbs) or brolucizumab (IVBr).This retrospective longitudinal study included 43 eyes of 43 patients (74.5 ± 9.8 years old, male to female ratio 31:12) with nAMD treated with IVBr (29 eyes) or IVRbs (14 eyes). OBF in the optic nerve head (ONH) and choroid (Ch) was measured with laser speckle flowgraphy (Softcare Co., Ltd., Fukutsu, Japan) before and one month after treatment. Changes in mean blur rate (MBR) before and after each treatment were tested using Wilcoxon's signed-rank tests and mixed-effect models for repeated measures.In the IVBr group, MBR was significantly reduced in both the ONH and Ch (p < 0.01). In contrast, the IVRbs group showed no significant change in MBR in either the ONH or Ch (p = 0.56, p = 1). The linear mixed effect model showed a significant interaction between time and anti-VEGF drugs for MBR in both the ONH and Ch (ONH: p = 0.04; Ch: p = 0.002). A post hoc pairwise comparison of estimated marginal means showed that MBR decreased significantly only after IVBr (p < 0.001).Our findings suggest that the short-term impact on OBF varies depending on the drug used for nAMD.